ATE423143T1 - Hyaluronsäurederivat mit einer urethanbindung - Google Patents

Hyaluronsäurederivat mit einer urethanbindung

Info

Publication number
ATE423143T1
ATE423143T1 AT04256686T AT04256686T ATE423143T1 AT E423143 T1 ATE423143 T1 AT E423143T1 AT 04256686 T AT04256686 T AT 04256686T AT 04256686 T AT04256686 T AT 04256686T AT E423143 T1 ATE423143 T1 AT E423143T1
Authority
AT
Austria
Prior art keywords
hyaluronic acid
acid derivative
urethane bond
biodegradable
müp
Prior art date
Application number
AT04256686T
Other languages
English (en)
Inventor
Jui-Hsiang Chen
Bin-Hong Tsai
Hsuen-Tseng Chang
Muh-Lan Chen
Yu-Hua Chen
Shu-Hua Jan
Mei-Jung Liu
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Application granted granted Critical
Publication of ATE423143T1 publication Critical patent/ATE423143T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT04256686T 2003-12-04 2004-10-29 Hyaluronsäurederivat mit einer urethanbindung ATE423143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0328168A GB2408741B (en) 2003-12-04 2003-12-04 Hyaluronic acid derivative with urethane linkage

Publications (1)

Publication Number Publication Date
ATE423143T1 true ATE423143T1 (de) 2009-03-15

Family

ID=29764606

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04256686T ATE423143T1 (de) 2003-12-04 2004-10-29 Hyaluronsäurederivat mit einer urethanbindung

Country Status (8)

Country Link
US (1) US7780982B2 (de)
EP (1) EP1538166B8 (de)
CN (2) CN100420486C (de)
AT (1) ATE423143T1 (de)
DE (1) DE602004019488D1 (de)
DK (1) DK1538166T3 (de)
GB (1) GB2408741B (de)
TW (1) TWI246516B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482018B2 (en) 2001-12-21 2009-01-27 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
ITPD20040312A1 (it) * 2004-12-15 2005-03-15 Fidia Advanced Biopolymers Srl Protesi e o supporto per la sostituzione, riparazione, rigenerazione del menisco
WO2006089167A1 (en) * 2005-02-18 2006-08-24 Cartilix, Inc. Glucosamine materials
US7713637B2 (en) * 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
CN101284883B (zh) * 2008-05-14 2011-02-16 西北大学 聚乳酸-壳聚糖接枝共聚物的制备方法
ITRM20080636A1 (it) * 2008-11-28 2010-05-29 Univ Palermo Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli.
EP2213315A1 (de) * 2009-01-30 2010-08-04 Mero S.r.L. Antibakterielles Hydrogel und dessen Verwendungen in der Orthopädie
US20100203150A1 (en) * 2009-02-06 2010-08-12 National Tsing Hua University Novel amphiphilic copolymers and fabrication method thereof
CZ302503B6 (cs) 2009-12-11 2011-06-22 Contipro C A.S. Zpusob prípravy derivátu kyseliny hyaluronové oxidovaného v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd a zpusob jeho modifikace
CZ2009836A3 (cs) 2009-12-11 2011-06-22 Contipro C A.S. Derivát kyseliny hyaluronové oxidovaný v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd, zpusob jeho prípravy a zpusob jeho modifikace
US8895069B2 (en) * 2011-05-16 2014-11-25 Postech Academy-Industry Foundation Drug delivery system using hyaluronic acid-peptide conjugate micelle
TWI561535B (en) * 2011-10-06 2016-12-11 Bvw Holding Ag Copolymers of hydrophobic and hydrophilic segments that reduce protein adsorption
US20140199349A1 (en) * 2011-12-29 2014-07-17 Industrial Technology Research Institute Ph-sensitive hyaluronic acid derivative and uses thereof
CZ303879B6 (cs) 2012-02-28 2013-06-05 Contipro Biotech S.R.O. Deriváty na bázi kyseliny hyaluronové schopné tvorit hydrogely, zpusob jejich prípravy, hydrogely na bázi techto derivátu, zpusob jejich prípravy a pouzití
CZ304512B6 (cs) 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití
CZ304654B6 (cs) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití
CZ2014150A3 (cs) 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
CZ2014451A3 (cs) 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
CZ309295B6 (cs) 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
CZ2015398A3 (cs) 2015-06-15 2017-02-08 Contipro A.S. Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin
CZ306662B6 (cs) 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
CZ308106B6 (cs) 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
CN107029235A (zh) * 2017-03-31 2017-08-11 武汉理工大学 多功能协同主动靶向给药系统及其制备和应用
CN107459590B (zh) * 2017-09-26 2021-03-23 华熙生物科技股份有限公司 一种透明质酸季铵盐的制备方法
CN109337082B (zh) * 2018-09-27 2021-05-25 福建拓烯新材料科技有限公司 一种玻尿酸-聚乳酸改性材料的制备方法
CN112159527B (zh) * 2020-10-29 2023-06-06 绍兴文理学院 一种含有透明质酸基团的聚甘油脂肪酸酯ha-pg及其合成方法和其在制备药物制剂中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
CA1238043A (en) * 1983-12-15 1988-06-14 Endre A. Balazs Water insoluble preparations of hyaluronic acid and processes therefor
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
IT1219942B (it) 1988-05-13 1990-05-24 Fidia Farmaceutici Esteri polisaccaridici
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
WO1993009176A2 (en) * 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
JP2855307B2 (ja) 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
IT1268955B1 (it) 1994-03-11 1997-03-18 Fidia Advanced Biopolymers Srl Esteri attivi di polisaccaridi carbossilici
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
SK282967B6 (sk) * 1997-04-10 2003-01-09 Du�An Bako� Hybridný resorbovateľný biokompatibilný materiál a spôsob jeho prípravy
ITPD980037A1 (it) * 1998-02-25 1999-08-25 Fidia Advanced Biopolymers Srl Acido ialuronico solfatato e i suoi derivati legati covalentemente a polimeri sintetici pe la preparazione di biomateriali e per il rivesti
JP3380899B2 (ja) * 2000-06-06 2003-02-24 独立行政法人産業技術総合研究所 ヒアルロン酸架橋化物
ITTS20010013A1 (it) * 2001-06-04 2002-12-04 Ct Ricerche Poly Tec H A R L S Nuovi derivati di ialuronano.
US7807722B2 (en) * 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof

Also Published As

Publication number Publication date
DK1538166T3 (da) 2009-05-11
GB0328168D0 (en) 2004-01-07
CN1284801C (zh) 2006-11-15
CN1876185A (zh) 2006-12-13
US7780982B2 (en) 2010-08-24
EP1538166B8 (de) 2009-04-08
US20050123505A1 (en) 2005-06-09
DE602004019488D1 (de) 2009-04-02
CN100420486C (zh) 2008-09-24
GB2408741B (en) 2008-06-18
GB2408741A (en) 2005-06-08
TWI246516B (en) 2006-01-01
TW200519129A (en) 2005-06-16
CN1624002A (zh) 2005-06-08
EP1538166A1 (de) 2005-06-08
EP1538166B1 (de) 2009-02-18

Similar Documents

Publication Publication Date Title
DE602004019488D1 (de) Hyaluronsäurederivat mit einer Urethanbindung
EP1281722A4 (de) Hyaluronsäuregel, verfahren zu dessen herstellung sowie das gel enthaltendes medizinisches material
DE602004000982D1 (de) Intranasale formulierung mit rotigotin
TW434023B (en) Preserved ophthalmic composition
DE60108651D1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
FI972326A0 (fi) Uusi amidinonaftyylijohdannainen tai sen suola
ES2032595T3 (es) Una solucion de peroxido de hidrogeno estabilizada.
EP0340741A3 (de) Polyäthylenglykolderivate, modifizierte Peptide und ihre Herstellung
TNSN03138A1 (en) PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT
DE60036194D1 (de) Benzimidazole mit vaskularisationszerstörender wirkung
NO2011022I2 (no) Pradofloksacin, dets farmasøytiske akseptable hydrater og syreaddisjonssalter så vel som alkall-, jordalkall-, sølvog guanidiniumsalter
DK110188D0 (da) High molecular weight prodrug derivatives of antiinflammatory drugs
CO5540368A2 (es) Composicion de liberacion sostenida y proceso para producirla
CH692199A8 (fr) Composes pyridiques et compositions pharmaceutique
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
ATE399020T1 (de) Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität
BR9611871A (pt) Diaminopirimidinas composições farmacêuticas contendo as mesmas e seu uso como antibactericidas
WO1999040073A3 (de) Tryptase-inhibitoren
ATE352287T1 (de) Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen
YU86792A (sh) Rastvor sparfloksacina, njegovo dobijanje i so sparfloksacina kao komponenta rastvora
DE3676335D1 (de) Auf mercaptoethansulfonsaeuren basierende pharmazeutische zusammensetzungen, organische abkoemmlinge von mercaptoethansulfonsaeuren sowie verfahren zu deren herstellung.
EP1219296A4 (de) Mittel zur hemmung der sebumproduktion
ATE151770T1 (de) Cephalosporinverbindungen und deren herstellung
ES2072332T3 (es) Derivados de la dibenzo(1,5)dioxocin-5-ona, su uso en medicamentos y procedimiento para su fabricacion.
CA2480123A1 (en) Highly aqueous liquid carrier formulations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties